Topical sirolimus therapy for epidermal nevus with features of acanthosis nigricans.
FGFR3
acanthosis nigricans
epidermal nevus
topical sirolimus
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
pubmed:
16
4
2019
medline:
21
1
2020
entrez:
16
4
2019
Statut:
ppublish
Résumé
We present a 4-year-old developmentally appropriate boy with short stature and widespread expanding epidermal nevus with features of acanthosis nigricans. He was found to have a mosaic mutation in FGFR3, the R248C variant. Despite several therapies, he continued to have growth, fissuring, and bleeding of the affected skin. Ultimately, topical sirolimus was attempted and found to improve thickness and overall symptoms.
Substances chimiques
FGFR3 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 3
EC 2.7.10.1
Sirolimus
W36ZG6FT64
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
554-555Informations de copyright
© 2019 Wiley Periodicals, Inc.